Cracking the Code of Life with AI: Using Frontier AI to Develop Therapies Addressing Diseases and Aging at the Same Time

How will generative AI and automation transform the pharmaceutical industry? In this presentation, Dr. Alex Zhavoronkov, CEO of Insilico Medicine, will detail how generative AI, automated platforms, and AI agents will accelerate the discovery of novel biological targets and the design of new molecular structures. He will explain how reinforcement learning and end-to-end automation will enable drug candidates to move into human clinical trials in record time while significantly reducing the cost and duration of the preclinical phase. The talk will also show how these AI capabilities will extend beyond traditional drug discovery into aging research, agricultural chemistry, and environmental sustainability. He will also introduce Science MMAI Gym, a domain-specific training environment designed to transform any causal or frontier Large Language Model (LLM) into a high-performance engine for real-world drug discovery and development tasks.Overall, the session will present a benchmark for the current and emerging capabilities of end-to-end AI in biotechnology and its potential to extend human longevity.